Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets - Research and Markets

DUBLIN--()--The "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" drug pipelines has been added to Research and Markets' offering.

The report "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Specifically, this report:

  • Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed.
  • Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.
  • Helps to identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.

Scope

  • The 3,100 products in active development, of which 989 are first-in-class and therefore act on completely novel targets, far exceed the scope of the current market. How will pipeline innovation affect the future cancer immunotherapies market?
  • There are 322 distinct first-in-class molecular targets currently being studied. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
  • Multiple types of cancer immunotherapies exist. Which of these are the most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
  • A significant number of first-in-class products have been identified with some prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 The Case for Innovation in the Oncology Market

4 Clinical and Commercial Landscape

5 Assessment of Pipeline Product Innovation

6 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration

7 First-in-Class Target Assessment

8 Deals and Strategic Consolidations

9 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xw6gqd/frontier_pharma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs, Immunosuppressive Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs, Immunosuppressive Drugs